MUC16 and ovarian carcinoma: Our study provides support for further optimization and testing of MUC16-targeted VLP vaccines based upon papillomavirus L1, including the safety of the approach in animals and its ability to prevent and limit the growth of mouse and human models of ovarian cancer.